Next-line protocol
Mild Nondisseminated Cutaneous Nocardiosis When TMP-SMX Monotherapy Has Not Achieved Clinical Improvement
Nondisseminated cutaneous nocardiosis is commonly acquired through direct inoculation — trauma or environmental skin disruption — and typically affects immunocompetent individuals with no apparent predisposing condition. Mild cases follow a chronic course and are managed in the outpatient setting. When initial single-agent therapy does not produce the expected response, a different therapeutic approach is indicated.
Clinical Scenario
Mild nocardiosis with nondisseminated cutaneous infection and no evidence of systemic spread. Patients in this scenario are often immunocompetent and present after a chronic course leading to diagnosis.
Why This Protocol Applies — Prior Therapy Did Not Succeed
Initial management with single-agent trimethoprim-sulfamethoxazole (TMP-SMX) monotherapy — the preferred first-line agent for nondisseminated cutaneous nocardiosis — did not achieve the required goal: signs of clinical improvement of the cutaneous infection. These presentations can be clinically indistinguishable from typical bacterial cellulitis or abscess and should be reconsidered among patients who do not respond to first-line therapy. This protocol defines the next therapeutic step following that failure.
Next-Step Approach (Partial Overview)
After TMP-SMX failure, the approach shifts to alternative or combination antibiotic therapy, drawing from agents to which most Nocardia isolates demonstrate susceptibility. Selection is adjusted based on species identification and antimicrobial susceptibility results. The full regimen — including agent selection, number of agents, and sequencing — is available in the structured protocol.
The clinical goal remains unchanged: signs of clinical improvement of the cutaneous infection.
References
DOI: 10.1093/cid/ciae643
- Importantly, nondisseminated cutaneous nocardiosis is commonly the result of direct inoculation, either through trauma or environmental skin disruption (eg, contact with a thorn).
- Accordingly, patients with nondisseminated cutaneous nocardiosis are commonly immunocompetent without apparent predisposing condition.
- Although no validated grading system for Nocardia severity exists, patients with mild nocardiosis are often managed in the outpatient setting, have a chronic course leading to diagnosis, and have nondisseminated infection.
- These may be clinically indistinguishable from "typical" bacterial cellulitis or abscess and should be considered among patients who do not respond to first-line therapy.
- Patients with TMP-SMX toxicity and yet-to-improve severe infection may be better served transitioning to alternative therapy, as patients with severe nocardiosis are underrepresented in the available data.
- Antibiotics that most Nocardia isolates demonstrate susceptibility to include amikacin, imipenem, linezolid, and trimethoprim-sulfamethoxazole (TMP-SMX).
- If combination therapy is started empirically, treatment can be narrowed to monotherapy, particularly if there are signs of clinical improvement.
View source ↗